Abstract
The introduction of the HPV vaccine in 2006 significantly decreased the prevalence of cervi-cal cancer in the populace. Preventive HPV vaccinations have produced impressive outcomes based on the HPV mechanism. However, there is still great room for development in thera-peutic vaccinations. In addition, there are still many issues and skepticisms surrounding the safety, efficacy, and sexuality of the HPV vaccine. In a nutshell, the human papillomavirus is a widespread human infection that poses a major risk to human health by increasing the risk of malignant tumors like cervical cancer. The WHO is developing a global strategy to eradi-cate cervical cancer, and the HPV vaccine is successful in reducing HPV infection and the ill-nesses it causes. Future commercial manufacture of the 14-valent HPV vaccination will greatly contribute to the implementation of this strategy.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call